Two cases of hepatitis B in patients with moderate to severe psoriasis treated with ustekinumab

Journal of Drugs in Dermatology

Volumn 11, Issue 12, 2012, Pages 1498-1501

  Opel, Daniel ^a   Economidi, Afrodite ^b   Chan, Daphne ^c   Wasfi, Yasmine ^c   Mistry, Sameer ^d   Vergou, Theognosia ^b   Antoniou, Christina ^b   Sofen, Howard ^e  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b UNIVERSITY OF ATHENS   (Greece)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d Janssen Cilag Ltd   (United Kingdom)

^e Dermatology Research Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYCLOSPORIN; ETRETIN; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; IMMUNOGLOBULIN M ANTIBODY; LACTATE DEHYDROGENASE; METHOTREXATE; PSORALEN; STEROID; USTEKINUMAB;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CASE REPORT; DISEASE SEVERITY; FATIGUE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS B; HUMAN; IMMUNE RESPONSE; INFECTION RISK; JAUNDICE; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER FUNCTION TEST; MAINTENANCE DRUG DOSE; MALE; PHOTOTHERAPY; PSORIASIS; SEROCONVERSION; SEROLOGY; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ALANINE TRANSAMINASE; ANTIBODIES, MONOCLONAL, HUMANIZED; ASPARTATE AMINOTRANSFERASES; BLOOD CHEMICAL ANALYSIS; CLINICAL TRIALS, PHASE III AS TOPIC; CLINICAL TRIALS, PHASE IV AS TOPIC; DNA, VIRAL; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HUMANS; LIVER FUNCTION TESTS; MALE; PSORIASIS; RISK; SKIN;

EID: 84871065050     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Amerio P, Amoruso G, Bardazzi F, et al. Detection and management of latent tuberculosis infections before biologic therapy for psoriasis [published online ahead of print January 31, 2012]. J Dermatolog Treat. doi:10.3109/09546634.2011.654107.
2. Gómez-Reino JJ, Carmona L, Angel Descalzo M; for Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 2007;57(5):756-761. (Pubitemid 46932080)
3. Hata A, Kuniyoshi M, Ohkusa Y. Risk of Herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study. Infection. 2011;39(6):537-544.
4. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009;301(7):737-744.
5. Cho YT, Chen CH, Chiu HY, Tsai TF. Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan. J Dermatol. 2012;39(3):269-273.
6. Prignano F, Ricceri F, Pescitelli L, Zanieri F, Lotti T. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients. Br J Dermatol. 2011;164(3):645-647.
7. Tsai TF, Wang TS, Hung ST, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci. 2011;63(1):40-46.
8. Yang YW, Keller JJ, Lin HC. Medical comorbidity associated with psoriasis in adults: a population-based study. Br J Dermatol. 2011;165(5):1037-1043.
9. Koziel MJ. Cytokines in viral hepatitis. Semin Liver Dis. 1999;19(2):157-169.
10. Carroll MB, Bond MI. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum. 2008;38(3):208-217.
11. Rossol S, Marinos G, Carucci P, Singer MV, Williams R, Naoumov NV. Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. J Clin Invest. 1997;99(12):3025-3033. (Pubitemid 27278680)
12. Loras C, Gisbert JP, Mínguez M, et al GETECCU (Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa) Group. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut. 2010;59(10):1340-1346.
13. Ojiro K, Naganuma M, Ebinuma H, et al. Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J Gastroenterol. 2008;43(5):397-401. (Pubitemid 351958904)
14. Chung SJ, Kim JK, Park MC, Park YB, Lee SK. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol. 2009;36(11):2416-2420.
15. Cassano N, Mastrandrea V, Principi M, et al. Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease. J Biol Regul Homeost Agents. 2011;25(2):285-289.
16. Abramson A, Menter A, Perrillo R. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management [published online ahead of print June 21, 2012]. J Am Acad Dermatol. doi:10.1016/j.jaad.2012.04.036.
17. Navarro R, Vilarrasa E, Herranz P, et al. Safety and effectiveness of ustekinumab and anti-tumor necrosis factor therapy in patients with psoriasis and chronic viral hepatitis b or c. A retrospective, multicentre study in a clinical setting [published online ahead of print September 17, 2012]. Br J Dermatol. doi:10.1111/bjd.12045.
18. Krueger GG, Langley RG, Leonardi C, et al; for CNTO 1275 Psoriasis Study Group. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356(6):580-592. (Pubitemid 46220818)
19. Leonardi CL, Kimball AB, Papp KA, et al; for PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1685-1674.
20. Papp KA, Langley RG, Lebwohl M, et al; for PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675- 1684. (Pubitemid 351671884)
21. Griffiths CEM, Strober BE, van de Kerkhof P, et al; for ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362(2):118-128.
22. Lebwohl M, Leonardi C, Griffiths CEM, et al. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. J Am Acad Dermatol. 2012;66(5):731-741.
23. Gordon KB, Papp KA, Langley RG, et al. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol. 2012;66(5):742-751.
24. Kimball AB, Gordon KB, Fakharzadeh S, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol. 2012;166(4):861-872.
25. Kimball AB, Papp KA, Wasfi Y, et al; on behalf of the PHOENIX 1 investigators. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to five years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. In press.
26. Paul C, Puig L, Luger T, et al. Ustekinumab is well-tolerated and effective in patients with moderate to severe plaque psoriasis inadequately responsive to methotrexate: Week 12 results from the TRANSIT study. Presented at the 20th Congress of the European Academy of Dermatology and Venereology; October 20-24, 2011; Lisbon, Portugal.
27. Igarashi A, Kato T, Kato M, Song M, Nakagawa H; The Japanese Ustekinumab Study Group. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol. 2012;39(3):242-252.
28. Tsai TF, Ho JC, Song M, et al PEARL Investigators. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci. 2011;63(3):154-163.
29. Hepatitis B-STD Treatment Guidelines 2006 page. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/std/treatment/2006/ hepatitis-b.htm. Accessed November 17, 2011.
30. Hepatitis B page. World Health Organization Web site. http://www.who.int/mediacentre/factsheets/fs204/en/index.html. Accessed November 17, 2011.
31. He D, Yan G, Wang Y. Serum levels of interleukin-12 in various clinical states with hepatitis B virus infection. Cell Immunol. 2012;272(2):162-165.
32. Wu JF, Wu TC, Chen CH, et al. Serum levels of interleukin-10 and interleukin-12 predict early, spontaneous hepatitis B virus e antigen seroconversion. Gastroenterology. 2010;138(1):165-72.e1-e3.
33. Zhang JY, Zhang Z, Lin F, et al. Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology. 2010;51(1):81-91.
34. Ge J, Wang K, Meng QH, Qi ZX, Meng FL, Fan YC. Implication of Th17 and Th1 cells in patients with chronic active hepatitis B. J Clin Immunol. 2010;30(1):60-67.
35. Servoss JC, Friedman LS. Serologic and molecular diagnosis of hepatitis B virus. Infect Dis Clin North Am. 2006;20(1):47-61. (Pubitemid 43343733)
36. Benson JM, Peritt D, Scallon BJ, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3(6):535-545.